CollPlant Biotechnologies (CLGN) Stock Price, News & Analysis

Company Overview

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.

Key Stats

• Today's Range: $2.56 to $2.71
• 50-Day Range: $1.35 to $3.15
• 52-Week Range: $1.31 to $5.45
• Volume: 12,283 shs
• Average Volume: 56,651 shs
• Market Capitalization: $33.58 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.50
• Consensus Rating: Buy

CollPlant Biotechnologies Stock Analysis - MarketRank™

CollPlant Biotechnologies scored higher than 51% of companies evaluated by MarketBeat, and ranked 530th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

CollPlant Biotechnologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

CollPlant Biotechnologies has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for CollPlant Biotechnologies are expected to grow in the coming year, from ($1.44) to ($0.56) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CollPlant Biotechnologies is -2.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CollPlant Biotechnologies is -2.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

CollPlant Biotechnologies has a P/B Ratio of 2.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.09% of the float of CollPlant Biotechnologies has been sold short.

Short Interest Ratio / Days to Cover

CollPlant Biotechnologies has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CollPlant Biotechnologies has recently decreased by 14.51%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CollPlant Biotechnologies does not currently pay a dividend.

Dividend Growth

CollPlant Biotechnologies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.09% of the float of CollPlant Biotechnologies has been sold short.

Short Interest Ratio / Days to Cover

CollPlant Biotechnologies has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CollPlant Biotechnologies has recently decreased by 14.51%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.5 / 5
• News Sentiment: -0.30

News Sentiment

CollPlant Biotechnologies has a news sentiment score of -0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for CollPlant Biotechnologies this week, compared to 0 articles on an average week.

MarketBeat Follows

5 people have added CollPlant Biotechnologies to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CollPlant Biotechnologies insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.60% of the stock of CollPlant Biotechnologies is held by insiders.

Percentage Held by Institutions

Only 21.69% of the stock of CollPlant Biotechnologies is held by institutions.

CLGN Stock Analysis - Frequently Asked Questions

How have CLGN shares performed this year?

CollPlant Biotechnologies' stock was trading at $3.60 on January 1st, 2025. Since then, CLGN stock has decreased by 26.7% and is now trading at $2.64.

How were CollPlant Biotechnologies' earnings last quarter?

CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ:CLGN) posted its quarterly earnings data on Wednesday, August, 20th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.29 by $0.57. The company earned $0.18 million during the quarter, compared to the consensus estimate of $8.91 million. CollPlant Biotechnologies had a negative trailing twelve-month return on equity of 94.08% and a negative net margin of 541.34%.

When did CollPlant Biotechnologies IPO?

CollPlant Biotechnologies (CLGN) raised $22 million in an initial public offering (IPO) on Friday, December 9th 2016. The company issued 3,500,000 shares at $6.23 per share. Ladenburg Thalmann served as the underwriter for the IPO and Roth Capital Partners was co-manager.

Who are CollPlant Biotechnologies' major shareholders?

CollPlant Biotechnologies' top institutional shareholders include Villere ST Denis J & Co. LLC (4.30%), Pinnacle Associates Ltd. (3.99%) and AMH Equity Ltd (1.26%).

How do I buy shares of CollPlant Biotechnologies?

Shares of CLGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of CollPlant Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CollPlant Biotechnologies investors own include Enovix (ENVX), Rambus (RMBS), COMPASS Pathways (CMPS), Ginkgo Bioworks (DNA), Globant (GLOB), Luminar Technologies (LAZR) and Saia (SAIA).

Company Calendar

• Last Earnings: 8/20/2025
• Today: 8/26/2025
• Next Earnings (Estimated): 11/03/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:CLGN
• CIK: 1631487
• Web: www.collplant.com
• Phone: 972732325600
• Fax: 972-73-232-5602
• Employees: 70
• Year Founded: N/A

Price Target and Rating

• Average Price Target for CollPlant Biotechnologies: $11.50
• High Price Target: $12.00
• Low Price Target: $11.00
• Potential Upside/Downside: +337.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.13)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$16.61 million
• Net Margins: -541.34%
• Pretax Margin: -541.34%
• Return on Equity: -94.08%
• Return on Assets: -68.62%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.60
• Quick Ratio: 4.40

Sales & Book Value

• Annual Sales: $510 thousand
• Price / Sales: 65.60
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.18 per share
• Price / Book: 2.23

Miscellaneous

• Outstanding Shares: 12,720,000
• Free Float: 11,495,000
• Market Cap: $33.45 million
• Optionable: Optionable
• Beta: 1.47